FindTrial
Sign In

Eritoran

DRUG3 trials

Sponsors

The University of Texas Health Science Center at San Antonio, UMC Utrecht

Conditions

Community-acquired Pneumonia, Influenza, COVID-19Insulin Sensitivity

Phase 2

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
TerminatedNCT02267317
The University of Texas Health Science Center at San AntonioInsulin Sensitivity
Start: 2015-01-31End: 2018-09-30Updated: 2020-03-04
The Role of TLR4 on Lipid-induced Insulin Resistance
CompletedNCT02321111
The University of Texas Health Science Center at San AntonioInsulin Sensitivity
Start: 2015-01-31End: 2018-09-30Updated: 2019-10-08

Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RecruitingNCT02735707
UMC UtrechtCommunity-acquired Pneumonia, Influenza, COVID-19
Start: 2016-04-11End: 2028-02-29Target: 20000Updated: 2024-07-12

Related Papers

Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Thorax2025-05-139 citations
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
Intensive Care Medicine2025-04-0132 citations
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.
2023-12-068 citations
Simvastatin in Critically Ill Patients with Covid-19
New England Journal of Medicine2023-10-2559 citations
Intravenous Vitamin C for Patients Hospitalized With COVID-19
JAMA2023-10-2545 citations
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
JAMA2023-04-1166 citations
The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
The Journal of Infectious Diseases2023-03-274 citations
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
JAMA2023-03-2192 citations
The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine
Canadian Journal of Cardiology2023-03-153 citations
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
2022-12-0128 citations
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
2022-09-2211 citations
Effect of acute TLR4 inhibition on insulin resistance in humans
Journal of Clinical Investigation2022-09-0615 citations
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
JAMA2022-03-22144 citations
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial
BMJ2022-01-0779 citations
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID‐19: Insights from the HOPE COVID‐19 Registry
International Journal of Clinical Practice2022-01-015 citations
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
JAMA2021-10-05208 citations
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Bristol Research (University of Bristol)2021-08-26586 citations
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
New England Journal of Medicine2021-08-041046 citations
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
New England Journal of Medicine2021-08-04947 citations
Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19.
2021-07-197 citations

6 more papers not shown